| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Director | Common Stock | 54K | $180K | $3.33 | Jun 18, 2024 | Direct |
| Summit Therapeutics Inc. | Director | Stock Option (right to buy) | 56.4K | $74.4K | $1.32 | Jan 2, 2024 | Direct |
| ESSA Pharma Inc. | Chief Medical Officer | Options | 200K | Mar 25, 2024 | Direct | ||
| Zymeworks Inc. | Director | Stock Option (Right to Buy) | 31K | Dec 10, 2024 | Direct | ||
| Zymeworks Inc. | Director | No securities are beneficially owned | 0 | Feb 8, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ZYME | Zymeworks Inc. | Dec 10, 2024 | 1 | $0 | 4 | Dec 12, 2024 | Director |
| PBYI | PUMA BIOTECHNOLOGY, INC. | Jun 18, 2024 | 1 | $0 | 4 | Jun 21, 2024 | Director |
| EPIX | ESSA Pharma Inc. | Mar 25, 2024 | 1 | $0 | 4 | Mar 28, 2024 | Chief Medical Officer |
| ZYME | Zymeworks Inc. | Feb 8, 2024 | 1 | $0 | 4 | Feb 9, 2024 | Director |
| ZYME | Zymeworks Inc. | Feb 8, 2024 | 0 | $0 | 3 | Feb 9, 2024 | Director |
| SMMT | Summit Therapeutics Inc. | Jan 2, 2024 | 2 | $28.2K | 4 | Jan 4, 2024 | Director |
| PBYI | PUMA BIOTECHNOLOGY, INC. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
| SMMT | Summit Therapeutics Inc. | Jan 3, 2023 | 2 | $27.3K | 4 | Jan 5, 2023 | Director |
| SMMT | Summit Therapeutics Inc. | Nov 15, 2022 | 2 | $0 | 4 | Nov 17, 2022 | Director |
| SMMT | Summit Therapeutics Inc. | Nov 15, 2022 | 0 | $0 | 3 | Nov 17, 2022 | Director |
| PBYI | PUMA BIOTECHNOLOGY, INC. | Jul 29, 2022 | 1 | $0 | 4 | Aug 2, 2022 | Director |
| PBYI | PUMA BIOTECHNOLOGY, INC. | Jul 29, 2022 | 0 | $0 | 3 | Aug 2, 2022 | Director |
| EPIX | ESSA Pharma Inc. | Jun 29, 2022 | 1 | $0 | 4 | Nov 1, 2022 | Chief Medical Officer |